Genetic polymorphisms related to the reninangiotensinaldosterone system and response to antihypertensive drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 4, 2010, Pages 439-460

  Taverne, Kim ^a   De Groot, Mark ^a,b   De Boer, Anthonius ^a   Klungel, Olaf ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

ACE; Antihypertensive drug; Intermediate outcome parameters; Pharmacogenetics; RAAS; Reninangiotensinaldosterone system

Indexed keywords

ALPHA ADDUCIN; ANGIOTENSIN 1 RECEPTOR; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CHLORIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DOBUTAMINE; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IMIDAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; PERINDOPRIL; PHOSPHORUS; POTASSIUM; PROTEIN KINASE WNK1; RAMIPRIL; TELMISARTAN;

ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CHLORIDE URINE LEVEL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DNA POLYMORPHISM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG RESPONSE; ESSENTIAL HYPERTENSION; GENE FREQUENCY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERTENSION; INDEL MUTATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PROTEINURIA; RECEPTOR GENE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; UREA NITROGEN BLOOD LEVEL;

ANTIHYPERTENSIVE AGENTS; HUMANS; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 77949881726     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903571670     Document Type: Review

References (63)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117(4):e25-146
2. Brugts JJ, den Uil CA, Danser AH, Boersma E. The renin-angiotensin- aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology 2009;112(4):303-312
3. Mellen PB, Herrington DM. Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 2005;23(7):1311-1325
4. Arnett DK, Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol 2006;44(2):107-118
5. Jeunemaitre X. Genetics of the human renin angiotensin system. J Mol Med 2008;86(6):637-641
6. Koopmans RP, Insel PA, Michel MC. Pharmacogenetics of hypertension treatment: a structured review. Pharmacogenetics 2003;13(12):705-713
7. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-1252
8. Sciarrone MT, Stella P, Barlassina C, et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003;41(3):398-403
9. Zhou Y, Wu SL, Liu JQ, et al. Possible association of ACE gene I/D polymorphism with blood pressure - lowering response to hydrochlorothiazide. Biomed Environ Sci 2007;20(5):351-356
10. Vormfelde SV, Sehrt D, Bolte D, et al. Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers. Eur J Clin Pharmacol 2006;62(3):195-201
11. Mondorf UF, Russ A, Wiesemann A, et al. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998;11(2):174-183
12. Todd GP, Chadwick IG, Higgins KS, et al. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol 1995;39(2):131-134
13. Kohno M, Yokokawa K, Minami M, et al. Association between angiotensinconverting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999;106(5):544-549
14. Ohmichi N, Iwai N, Uchida Y, et al. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997;10(8):951-955
15. Sasaki M, Oki T, Iuchi A, et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 1996;14(12):1403-1408
16. Ueda S, Meredith PA, Morton JJ, et al. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998;98(20):2148-2153
17. Weekers L, Bouhanick B, Hadjadj S, et al. Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. Diabetes 2005;54(10):2961-2967
18. Manunta P, Barlassina C, Bianchi G. Adducin in essential hypertension. FEBS Lett 1998;430(1-2):41-44
19. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997;349(9062):1353-1357
20. Shin MH, Chung EK, Kim HN, et al. Alpha-adducin Gly460Trp polymorphism and essential hypertension in Korea. J Korean Med Sci 2004;19(6):812-814
21. Glorioso N, Manunta P, Filigheddu F, et al. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999;34(4 Pt 1):649-654
22. Sugimoto K, Hozawa A, Katsuya T, et al. Alpha-adducin Gly460Trp polymorphism is associated with low renin hypertension in younger subjects in the Ohasama study. J Hypertens 2002;20(9):1779-1784
23. Rejnmark L, Vestergaard P, Pedersen AR, et al. Dose-effect relations of loop-and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latinsquare multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest 2003;33(1):41-50
24. Glorioso N, Filigheddu F, Cusi D, et al. Alpha-adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. Hypertension 2002;39(2 Pt 2):357-362
25. Velazquez H. Thiazide diuretics. Ren Physiol 1987;10(3-4):184-197
26. Subramanya AR, Yang CL, McCormick JA, Ellison DH. WNK kinases regulate sodium chloride and potassium transport by the aldosteronesensitive distal nephron. Kidney Int 2006;70(4):630-634
27. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 2005;46(4):758-765
28. Jastrzebskal M, Widecka K, Naruszewicz M, et al. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. Nutr Metab Cardiovasc Dis 2004;14(5):259-269
29. Yu H, Zhang Y, Liu G. Relationship between polymorphism of the angiotensinconverting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients. Hypertens Res 2003;26(11):881-886
30. Ha SK, Yong Lee S, Su Park H, et al. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulindependent diabetes mellitus. Nephrol Dial Transplant 2000;15(10):1617-1623
31. Haas M, Yilmaz N, Schmidt A, et al. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press Res 1998;21(1):66-69
32. Stavroulakis GA, Makris TK, Krespi PG, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000;14(4):427-432
33. Perna A, Ruggenenti P, Testa A, et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. Kidney Int 2000;57(1):274-281
34. Yoshida H, Mitarai T, Kawamura T, et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995;96(5):2162-2169
35. van Essen GG, Rensma PL, de Zeeuw D, et al. Association between angiotensinconverting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996;347(8994):94-95
36. van der Kleij FG, Navis GJ, Gansevoort RT, et al. ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients. Nephrol Dial Transplant 1997;12(Suppl 2):42-46
37. Jacobsen P, Rossing K, Rossing P, et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998;53(4):1002-1006
38. Penno G, Chaturvedi N, Talmud PJ, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID randomized controlled trial. EURODIAB controlled trial of lisinopril in IDDM. Diabetes 1998;47(9):1507-1511
39. Dudley C, Keavney B, Casadei B, et al. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996;14(2):259-262
40. Hingorani AD, Jia H, Stevens PA, et al. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995;13(12 Pt 2):1602-1609
41. Yu H, Lin S, Liu G, et al. T1198C polymorphism of the angiotensinogen gene and antihypertensive response to angiotensin-converting enzyme inhibitors. Hypertens Res 2005;28(12):981-986
42. Woodiwiss AJ, Nkeh B, Samani NJ, et al. Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin. J Hypertens 2006;24(6):1057-1064
43. Jain S, Tang X, Narayanan CS, et al. Angiotensinogen gene polymorphism at -217 affects basal promoter activity and is associated with hypertension in African-Americans. J Biol Chem 2002;277(39):36889-36896
44. Kramkowski K, Mogielnicki A, Buczko W. The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 2006;57(4):529-539
45. Gluszek J, Jankowska K. Is there relationship between the A1166C polymorphism of the angiotensin II receptor AT1 and plasma renin activity, insulin resistance and reduction of blood pressure after angiotensin-converting enzyme inhibitor therapy? Pol Arch Med Wewn 2008;118(4):194-200
46. Parving HH, de Zeeuw D, Cooper ME, et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 2008;19(4):771-779
47. Park HC, Choi HY, Kim BS, et al. Antiproteinuric effect of losartan in nondiabetic renal disease is not dependent on ACE insertion/deletion polymorphism. Kidney Blood Press Res 2006;29(4):216-224
48. Andersen S, Tarnow L, Cambien F, et al. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int 2002;62(1):192-198
49. Nakamura Y, Tamaki S, Uchida Y, et al. Angiotensin converting enzyme genotype influences the response to the angiotensin II receptor antagonist losartan in patients with hypertension. Hypertens Res 2004;27(3):137-140
50. Redon J, Luque-Otero M, Martell N, Chaves FJ. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005;5(1):14-20
51. Haneda M, Kikkawa R, Sakai H, Kawamori R. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Res Clin Pract 2004;66(1):87-95
52. Inoue I, Nakajima T, Williams CS, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997;99(7):1786-1797
53. Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001;19(10):1783-1787
54. Miller JA, Thai K, Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999;56(6):2173-2180
55. Bonnardeaux A, Davies E, Jeunemaitre X, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24(1):63-69
56. Leenen FH, Redmond DP, McDonald RH Jr, Alpha and beta adrenergic-induced renin release in man. Clin Pharmacol Ther 1975;18(1):31-38
57. Johnson JA, Zineh I, Puckett BJ, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003;74(1):44-52
58. Liu J, Liu ZQ, Yu BN, et al. Beta1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 2006;80(1):23-32
59. Bruck H, Leineweber K, Temme T, et al. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol 2005;46(11):2111-2115
60. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002;62(5):1718-1723
61. Lynch AI, Arnett DK, Davis BR, et al. Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: the GenHAT study. Ann Hum Genet 2007;71(Pt 6):735-745
62. Jalil JE, Ocaranza MP, Oliveri C, et al. Neutral endopeptidase and angiotensin I converting enzyme insertion/deletion gene polymorphism in humans. J Hum Hypertens 2004;18(2):119-125
63. Lee YJ, Tsai JC. Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitorrelated cough in Chinese female patients with non-insulin-dependent diabetes mellitus. Metabolism 2001;50(11):1346-1350